Home
News
Create
Screeners
Insights
Genomic Valley Biotech
25.
52
-0.85
(-3.22%)
Market Cap
₹7.84 Cr
PE Ratio
-175.80
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-3.22%
1M
-6.00%
6M
-12.30%
1Y
-59.49%
5Y
+13.42%
View Company Insights
Latest news about Genomic Valley Biotech
Genomic Valley Biotech Limited Submits Q4 FY26 SEBI Compliance Certificate to BSE
Apr 14, 2026
Genomic Valley Biotech Limited filed its Q4 FY26 compliance certificate with BSE on April 14th, 2026, pursuant to SEBI Regulation 74(5) for the quarter ended March 31st, 2026. The certificate, signed by Managing Director Yogesh Agrawal, was accompanied by confirmation from registrar Beetal Financial & Computer Services confirming proper processing of dematerialization requests and compliance with prescribed timelines for share transfer processes.
Genomic Valley Biotech Limited Files SEBI Declaration Under Takeover Regulations for FY26
Apr 03, 2026
Genomic Valley Biotech Reports Q3FY26 Results with ₹1.05 Lakh Profit; Director Steps Down
Jan 15, 2026
Genomic Valley Biotech Reports Q1 FY26 Results, Announces Key Appointments
Aug 07, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO